# US 2010/0168135 A1 · Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168135 A1
- Document ID: US20100168135A1
- Status: Published application
- Kind: A1
- Application number: 12/638,219
- Filed: 2009-12-15
- Published: 2010-07-01
- Earliest claimed: 2008-12-15
- Inventors: Kim Nicholas Green; Tilman Oltersdorf; Eckard Weber
- Web page: https://patentgrep.com/patent/US20100168135A1

## CPC

- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G01N 33/5058: {Neurological cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a method of inducing cleavage of amyloid precursor protein to produce an approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein in a subject, the method comprising administering a heterocyclic compound or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof, wherein the approximately 17 kilodalton fragment includes the carboxyterminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence. Also provided is a screening method for identifying compounds induce cleavage of amyloid precursor protein to produce the approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein.

## Claims

### Claim 1

A method of inducing cleavage of amyloid precursor protein to produce an approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein in a subject, the method comprising administering a heterocyclic compound having the general Formula (I):
or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof,
wherein the approximately 17 kilodalton fragment includes the carboxyterminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence, and wherein each of Rx, R1, R2, R3, R4 are as defined herein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the heterocyclic compound is spiro(imidazo[1,2-a]pyridin-2(3H)-one-3,2′-indan).

### Claim 3 (depends on 1)

The method of claim 1, wherein administering said heterocyclic compound results in a decrease in the production of one or more of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has Alzheimer's Disease.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject has been diagnosed with Alzheimer's Disease.

### Claim 6

An isolated approximately 17 kilodalton amyloid precursor protein fragment that includes the carboxyterminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence.

### Claim 7 (depends on 6)

A composition comprising the fragment of claim 6.

### Claim 8

A method for screening for a compound that cleaves amyloid precursor protein to generate an approximately 17 kilodalton fragment of amyloid precursor protein, said method comprising:
(a) exposing cells that produce amyloid precursor protein or fragments thereof to a test compound, and
(b) detecting the amount of the approximately 17 kilodalton fragment,
wherein the approximately 17 kilodalton fragment, includes the carboxyterminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence, and
wherein an increase in the amount of the approximately 17 kilodalton fragment in cells exposed to the compound, relative to the amount of the approximately 17 kilodalton fragment in cells that are not exposed to the compound, indicates that the compound induces cleavage of amyloid precursor protein to generate the approximately 17 kilodalton fragment.

### Claim 9 (depends on 8)

The method of claim 8, further comprising (c) determining whether the amount of one or more of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in cells exposed to the compound is decreased, relative to the amount of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in cells that are not exposed to the compound.

### Claim 10 (depends on 1)

The method of claim 1, wherein said screening method is carried out in vitro.

### Claim 11 (depends on 8)

The method of claim 8, further comprising (c) determining whether the amount of one or more of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in the cell culture lysate of cells exposed to the compound is decreased, relative to the amount of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in the cell culture medium of cells that are not exposed to the compound.

### Claim 12 (depends on 8)

The method of claim 8, wherein said screening method is carried out in a high-throughput manner.

### Claim 13

A method for screening for a compound that cleaves amyloid precursor protein to generate an approximately 17 kilodalton fragment of APP, the method comprising:
(a) exposing cells that produce amyloid precursor protein or fragments thereof to a test compound, and
(b) detecting the approximately 17 kilodalton fragment,
wherein the approximately 17 kilodalton fragment includes the carboxy-terminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence, and
wherein the presence of the approximately 17 kilodalton fragment of cells exposed to the compound, relative to the absence of the approximately 17 kilodalton fragment in cells that are not exposed to the compound, indicates that the compound induces cleavage of amyloid precursor protein to generate the approximately 17 kilodalton fragment.

### Claim 14 (depends on 13)

The method of claim 13, further comprising (c) determining whether the amount of one or more of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in cells exposed to the compound is decreased, relative to the amount of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in cells that are not exposed to the compound.

### Claim 15 (depends on 13)

The method of claim 13, wherein said screening method is carried out in vitro.

### Claim 16 (depends on 13)

The method of claim 13, further comprising (c) determining whether the amount of one or more of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in the cell culture lysate of cells exposed to the compound is decreased, relative to the amount of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein in the cell culture medium of cells that are not exposed to the compound.

### Claim 17 (depends on 13)

The method of claim 13, wherein said screening method is carried out in a high-throughput manner.

### Claim 18

A method of inducing cleavage of amyloid precursor protein to produce an approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein in a subject, the method comprising administering a compound that is not a compound having the general Formula (I):
or a pharmaceutically acceptable salt, hydrate or prodrug thereof,
wherein each of Rx, R1, R2, R3, R4 are as defined herein.

### Claim 19 (depends on 18)

The method of claim 18, wherein administering said heterocyclic compound results in a decrease in the production of one or more of Aβ1-42, Aβ1-40, the C99 fragment of amyloid precursor protein, or the C83 fragment of amyloid precursor protein.

### Claim 20 (depends on 1)

The method of claim 1, wherein the subject has Alzheimer's Disease.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject has been diagnosed with Alzheimer's Disease.
